Careers  |  Sign In  |  Register

Osteoporosis Treatment

FDA: No Causal Link to Heart Problems

The FDA reviewed spontaneous post-marketing reports of atrial fibrillation reported in association with oral and intravenous bisphosphonates and did not identify a population of bisphosphonate users at increased risk of atrial fibrillation.

References and Resources
Early Communication of an Ongoing Safety Review

Early Communication of an Ongoing Safety Review. Bisphosphonates: Alendronate (Fosamax, Fosamax Plus D), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Risedronate (Actonel, Actonel W/Calcium), Tiludronate (Skelid), and Zoledronic acid (Reclast, Zometa). FDA Website, Oct 2007.
Click Here to read the update.

Sponsored by The Doctor’s Channel